Skip to main content Accessibility help
×
Home

N Alpha Methyl Histamine Versus Propranolol in Migraine Prophylaxis

  • R.O. Millán-Guerrero (a1), R. Isais-Millán (a2), B. Guzmán-Chávez (a2) and G. Castillo-Varela (a1)

Abstract

Objectives:

To compare the efficacy and tolerability of the subcutaneous administration of N alpha methyl histamine versus oral propranolol in the treatment of migraine prophylaxis.

Background:

N alpha methyl histamine has a selective affinity for H3 receptors and could constitute a new therapeutic drug in migraine prophylaxis.

Methods:

Sixty patients with migraine were selected and enrolled in a 12-week double-blind controlled clinical trial to evaluate the efficacy of subcutaneous administration of N-alpha methyl histamine (1 to 3 ug twice a week ) n=30, compared to administration of 120 mg/day of oral propranolol n=30. the variables were: headache intensity, frequency of attacks, duration of migraine attacks and analgesic intake.

Results:

fifty five patients completed the study. the data collected during the 4th week of treatment revealed that N alpha methyl histamine and propranolol caused a significantly (p<0.01) greater reduction between the basal values and final values of every variable studied.

Conclusions:

Both N alpha methyl histamine and propranolol are similarly effective in reducing or eliminating the headache in migraine prophylaxis. low doses of N-alpha methyl histamine injected subcutaneously may represent a novel and effective therapeutic alternative in migraine patients and may lay the clinical and pharmacological groundwork for the use of H3 receptor agonist in migraine prophylaxis.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      N Alpha Methyl Histamine Versus Propranolol in Migraine Prophylaxis
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      N Alpha Methyl Histamine Versus Propranolol in Migraine Prophylaxis
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      N Alpha Methyl Histamine Versus Propranolol in Migraine Prophylaxis
      Available formats
      ×

Copyright

References

Hide All
1.Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia. 1988;8 (Suppl. 7):196.
2.International classification of headache disorders-II. Cephalalgia. 2004;24(Supp 1):152.
3.Lipton, RB, Bigal, ME.Ten lessons on the epidemiology of migraine. Headache. 2007;47(Suppl. 1):S29.
4.Linde, M, Gustavsson, A, Stovner, LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:70311.
5.Lipton, RB, Bigal, ME, Diamond, M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:3439.
6.Holland, S, Silberstein, SD, Freitag, F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:134653.
7.Buchanan, TM, Ramadan, M.Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006;26:18898.
8.Lohman, J, Van der Kuy-de Ree, M.Patterns of specific antimigraine drug use-a study based on the records of 18 community pharmacies. Cephalalgia. 2005;25:21418.
9.Shields, KG, Goadsby, PJ.Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128:8697.
10.Sanchez-Del-Rio, M, Reuter, U, Moskowitz, MA.New insights into migraine pathophysiology. Curr Opin Neurol. 2006; 19:2948.
11.Moskowitz, MA.The neurobiology of vascular head pain. Ann Neurol. 1984;16:15768.
12.Millán, GR, Isais, CM, Antonio, OA, et al. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study. Headache. 1999;39:57680.
13.Ishikawa, S, Speralakis, N.A novel class H3 of histamine receptors on perivascular nerve terminals. Nature. 1987;327:15860.
14.Göthert, M, Garbarg, M, Hey, J A, et al. New aspects of the role of histamine in cardiovascular function: Identification, characterization, and potential pathophysiological importance of H3 receptors. Can J Pharmacol. 1995;73:55864.
15.Millán, GR, Pineda, LA, Trujillo, HB, et al. N alpha methyl histamine safety and efficacy in migraine prophylaxis: Phase I and Phase II studies. Headache. 2003;43:38994.
16.Millán-Guerrero, RO, Isais-Millán, R, Trujillo Hernández, B, et al. N alpha methyl histamine safety and efficacy in migraine prophylaxis: Phase III study. Can J Neurol Sci. 2006;33:1959.
17.Silberstein, SD, Holland, S, Freitag, F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:133745.
18.International Classification of Headache Disorders, Olesen, J.International Classification of Headache Disorders, Second Edition (ICHD-2): current status and future revisions. Cephalalgia. 2006;26:140910.
19.Lipchik, GL.Nicholson, RA, Penzien, DB.Allocation of patients to conditions in headache clinical trials: randomization, stratification and treatment matching. Headache. 2005;45: 41928.
20.International Headache Society committee on clinical trials in migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia. 1991;11:112.
21.Hulley, SB, Gove, S, Cummings, SR.Elección de los individuos que participarán en el estudio: especificación y muestreo. En: Hulley, SB, Cummings, SR, editors. Diseño de la Investigación Clínica. España: Harcourt Brace; 1997. p.2155.
22.Lassen, LH.Thomsen, LL.Olesen, J.Histamine induce migraine via the H1 receptor. Support for the NO hypothesis of migraine. Neuroreport. 1995;6:14759.
23.Thomsen, LL, Olesen, JB.Nitric oxide in primary headache. Curr Opin Neurol. 2001;14:31521.
24.Peroutka, SJ.Neurogenic inflammation and migraine: Implications for therapeutics. Mol Interv. 2005;5:30411.
25.Arrang, JM, Garbarg, M, Schwartz, JC.Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature. 1983;302:8327.
26.Arrang, J-M, Garbarg, M, Schwartz, J-C.Autoinhibition of histamine synthesis mediated by presynaptic H3-receptors. Neuroscience. 1987;23:14957.
27.Waeber, CH, Moskowitz, MA.Migraine as an inflammatory disorder. Neurology. 2005;64(Suppl 2); S915.
28.West, RE, Zweig, A, Shih, N-Y, et al. Identification of two H3-histamine receptor subtypes. Mol Pharmacol. 1990;38:61013.
29.Dimitriadou, V, Rouleau, A, Trung, Dam, et al. Functional relationship between mast cells and C-sensitive nerve fibers evidenced by histamine H3-receptor modulation in rat lung and spleen. Clin Sci. 1994;87:15163.
30.Tokita, S, Takahashi, K, Kotani, H.Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine h3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci. 2006;101:1218.
31.Olesen, J, Diener, HC, Husstedt, IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New Engl J Med. 2004;350:110410.
32.Goadsby, PJ.Recent advances in the diagnosis and management of migraine. Brit Med J. 2006;332:259.
33.Loder, E.Prophylaxis: headaches that never happen. Headache. 2008;48:6946.
34.Marmura, MJ, Silbertein, S.Current understanding and treatment of headache disorders. Neurol Clin Pract. 2011;76 (Suppl 2):S316.
35.Durham, PL, Masterson, CG.Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment. Headache. 2013;53:6780.
36.Sieberg, CHB, Huguet, A, Von Baeyer, CL, et al. Psychological interventions for headache in children and adolescents. Can J Neurol Sci. 2012;39:2634.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed